KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 3 filers reported holding KALA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,000 | -36.4% | 64,873 | -13.1% | 0.00% | -50.0% |
| Q2 2022 | $22,000 | -88.7% | 74,636 | -46.9% | 0.00% | -85.7% |
| Q1 2022 | $194,000 | +26.8% | 140,511 | +11.3% | 0.01% | -12.5% |
| Q4 2021 | $153,000 | +13.3% | 126,231 | +884.9% | 0.02% | 0.0% |
| Q2 2020 | $135,000 | +55.2% | 12,816 | -45.5% | 0.02% | +100.0% |
| Q4 2019 | $87,000 | -56.5% | 23,500 | +15.7% | 0.01% | -33.3% |
| Q3 2018 | $200,000 | – | 20,310 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |